Cover Image
市場調查報告書

潰瘍性大腸炎:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 (2016年2月)

Ulcerative Colitis: Update Bulletin [Feb 2016]

出版商 FirstWord 商品編碼 353278
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
潰瘍性大腸炎:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 (2016年2月) Ulcerative Colitis: Update Bulletin [Feb 2016]
出版日期: 2016年02月01日 內容資訊: 英文
簡介

本最新趨勢簡報,調查與潰瘍性大腸炎的治療藥相關最新的事件和關鍵意見領袖 (KOL) 對其見解的彙整。

調查內容範例

  • KOL怎麼認識潰瘍性大腸炎市場上Stelara的可能性?
  • 怎麼認識潰瘍性大腸炎市場上ABP 501 (Humira的生技仿製藥) 的可能性?
  • KOL認為Humira的生技仿製藥帶給市場什麼影響?
  • KOL對由首發藥轉移生技仿製藥的所謂「轉換實驗」怎麼想?
  • 這些實驗是否成為提高潰瘍性大腸炎的生技仿製藥處方的信賴
  • KOL對於Janssen的Remicade的生技仿製藥的CT-P13FDA的核准建議決策的見解為何?
  • KOL對QBECO的作用機制的見解為何?
  • 受承認的QBECO的治療範例為何?
  • Protagonist Therapeutics的PTG 100臨床性魅力是什麼?
目錄
Product Code: 596200562

Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson's Stelara (ustekinumab) in Crohn's disease and the launch of a new study looking at use of the therapy in patients with UC; the recent filing in the US and EU for Amgen's ABP 501 (a proposed adalimumab biosimilar); the FDA advisory committee's decision to recommend approval of Celltrion's CT-P13 (a proposed infliximab biosimilar); as well as opinions on the early development of both Qu Biologics' QBECO and Protagonist Therapeutics' PTG 100.

Key Questions Answered in this Update Bulletin:

  • How do KOLs perceive Stelara's potential in the UC market?
  • How do KOLs perceive the potential of ABP 501 (a Humira biosimilar) in the UC marketplace?
  • What impact do they believe the arrival of biosimilar Humira will have on the market?
  • What do KOLs think of the so-called ‘switching trials,' which see patients transitioned from an originator therapy to a biosimilar?
  • Do such trials boost confidence in prescribing biosimilars in UC?
  • What are KOLs' opinions of an FDA committee's decision to recommend approval of CT-P13, a biosimilar version of Janssen's Remicade?
  • What do KOLs think of the mechanism of action behind QBECO?
  • Where in the treatment paradigm might QBECO be placed if approved?
  • How clinically attractive is Protagonist Therapeutics' PTG 100?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Back to Top